More recently, agents within the GLP-1 receptor agonist class have also demonstrated cardiovascular and kidney benefits in completed cardiovascular outcome trials
Lately, GLP-1 medications have become a major topic of conversation
While often inexpensive, their efficacy and long-term benefits are highly uncertain
Firstly, our study further strengthen the evidence of well-designed RCTs of ALC in HE and introduce the view and methodology of evidence-based medicine (EBM) when compared with a previous review included 3 clinical trials reported in 2008.28 Secondly, perhaps more and more investigators from different countries will be interested and highlight the role of ALC and conduct studies with far more important findings, so as to provide another choice drug for HE
However, this journey isn't without its hurdles
Username or email address *Required Password *Required Remember me Log in Lost your password